Printer Friendly
The Free Library
14,529,347 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Fuji Keizai Publishes Report on Disease Prevention/Health Food Market in Japan.


Tokyo, Japan, Dec 27, 2005 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Japanese market researcher Fuji Keizai announced on December 27 that it has published a report on the disease prevention and health food market in Japan.

The report estimates that the market for disease prevention and health food products reached 2,218.6 billion yen ($19.1 bil) in 2004, and is expected to decline 2% to 2,180.9 billion yen ($18.8 bil) in 2005.

By sector, the functional food segment will rise from 567 billion yen ($4.9 bil) in 2004 to 585.9 billion yen ($5.0 bil) in 2005; the quasi-drug segment will also increase from 140.8 billion yen ($1.2 bil) to 141.2 billion yen ($1.2 bil), the health-oriented food segment will fall from 1,299.5 billion yen ($11.2 bil) to 1,248 billion yen ($10.7 bil), the OTC OTC

See: Over-the-counter.


OTC

See over-the-counter market (OTC).
 product segment will decline from 211.4 billion yen ($1.8 bil) to 205.8 billion yen ($1.7 bil).

By company, Otsuka Pharmaceutical will rank top, followed by Yakult Honsha, Meiji Dairies Meiji Dairies Corporation (明治乳業株式会社  , Taisho Pharmaceutical Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社   and Suntory.

The 221-page report is available, in Japanese for 99,000 yen ($853) and 109,000 yen ($915) with a supplemental CD-ROM CD-ROM: see compact disc.
CD-ROM
 in full compact disc read-only memory

Type of computer storage medium that is read optically (e.g., by a laser).
.

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Dec 28, 2005
Words:214
Previous Article:Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent.
Next Article:Daiichi Wins Lawsuit Against Mylan Pharmaceuticals Regarding Patents for Levofloxacin.



Related Articles
Fuji Keizai Releases Report on Specified Health Food Market in Japan.
Fuji Keizai Analyzes Functional Cosmetics Market in Japan.
Fuji Keizai Analyzes Health/Beauty-oriented Food Market in Japan.
Fuji Keizai Releases Report on Skin Care Product Trends in Japan.
Fuji Keizai Releases Report on Japanese Immunoassay Market.
Fuji Keizai Releases Reports on Japanese Health and Beauty Food Market.
Fuji Keizai Releases Report on Japanese Cosmetics Market.
Fuji Keizai Releases Report on Food Inspection Market in Japan.
Fuji Keizai Releases Report on Japanese Cosmetics Market.
Fuji Keizai Releases Reports on OTC Drug Market in Japan.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles